Download PDF
Thromb Haemost 1960; 4(03): 303-322
DOI: 10.1055/s-0038-1654512
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Disappearance of Factor V Activity after Incubation of Plasma with Heparin and Heparinoids[*]

R Holemans
1   Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium
,
C Vermylen
1   Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium
,
M Verstraete   **
1   Laboratory of Physiopathology of the Department of Medicine (Prof. J. Vandenbroucke), University of Louvain, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
17 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

1. Heparin and heparinoids, added to oxalated or citrated plasma produce in this plasma an inactivation of factor V; this inactivation is progressive and directly related to the length of incubation.

The rate of inactivation of factor V is directly proportional to the quantity of anticoagulant added.

2. When quantities with identical anticoagulant activity in the thromboplastin-calcium clotting time are compared, heparin proves to have a stronger effect than heparinoids.

3. The inactvation of factor V in plasma by heparin or heparinoïds is an irreversible process, which cannot be nullified by addition of protamine sulphate.

* Supported by grant-in-aid of the Fonds de la Recherche Clinique Médicale.


** Associé du Fonds National de la Recherche Scientifique.


 

  • References

  • (1) Howell W. H, Holt E. Two new factors in blood coagulation: heparin and proantithrombin. Amer. J. Physiol. 47: 328-341 1918;
    PubMedGoogle Scholar
  • (2) Nilsson L, Wenckert A. Demonstration of a Heparin-like Anticoagulant in Normal Blood. Acta med. scand. Suppl. 297 1954;
    PubMedGoogle Scholar
  • (3) Wenckert A, Nilsson I. M. Thromboplastin and Russell Viper Venom. Investigation on the activation of Prothrombin. Scand. J. clin. Lab. Invest. 7 Suppl. 15 1955;
    CrossrefPubMedGoogle Scholar
  • (4) Dyckerhoff H, Miehler H, Steiner R. Über die Gerinnung des Blutes. Thrombin. Biochem. Z. 297: 342-346 1938;
    PubMedGoogle Scholar
  • (5) Schullze H. E, Schwieck G. Über den Mechanismus der Thrombinbildung im isolierten System. Hoppe-Seyler’s Z. Physiol. Chem. 289: 26-43 1951;
    PubMedGoogle Scholar
  • (6) Laki K. Chemistry of Prothrombin and some of its reactions. Physiol. Reviews 34: 730-735 1954;
    PubMedGoogle Scholar
  • (7) Brinkhous K. M, Smith H. P, Warner E. D, Seegers W. H. The inhibition of blood clotting: an unidentifed substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin. Amer. J. Physiol. 125: 683-687 1939;
    PubMedGoogle Scholar
  • (8) Marbet R, Winterstein A. Über die Wirkung von Antikoagulantien des Heparintypus auf die 1. Phase der Blutgerinnung. Helv. physiol, pharmacol. Acta 10: 528-542 1952;
    PubMedGoogle Scholar
  • (9) Winterstein A. Symposium sur les Macromolécules: Héparine et Héparinoïdes. Centenaire de l’Institut National Genevois; Volume hors-série 93-109 1954
    Google Scholar
  • (10) Brambell C. E, Corwin A. H, Capone V. A. Mechanism of the Action of Heparin as an etiological Basis for Homeostatis (Hemorrhage and Thrombosis). Amer. J. med. Sci. 230: 276 1955;
    CrossrefPubMedGoogle Scholar
  • (11) Beaumont J. L, Beaumont V. Le sulphate de dextrane. Son action anticoagulante clinique étiologique. Le Sang 28: 61-77 1957;
    PubMedGoogle Scholar
  • (12) Michaelis J. Diethylobarbiturate Buffer. J. biol. Chem. 87: 33 1930;
    PubMedGoogle Scholar
  • (13) Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta haemat. 6: 1-18 1951;
    CrossrefPubMedGoogle Scholar
  • (14) Wolf P. A modification for Routine Laboratory Use of Stefanini's Method of estimating Factor V in human oxalated Plasma. J. clin. Path. 6: 34-38 1953;
    CrossrefPubMedGoogle Scholar
  • (15) Holemans R, Vermylen C, Verstraete M. Antithrombin Activity of Heparin and Heparinoïds. Is prepared.
    PubMedGoogle Scholar
  • (16) Holemans R, Verstraete M. Influence of heparin and heparinoïds on thromboplastin formation. Is prepared.
    PubMedGoogle Scholar
  • (17) Douglas A. S. The action of Heparin in the Prevention of Prothrombin Conversion. J. clin. Invest. 35: 533 1956;
    CrossrefPubMedGoogle Scholar
  • (18) Nieth H, Mammen E, Gross R. Zur Heparinisierung des Blutes bei der extrakorporealen Hämodialyse. Klin. Wschr. 36: 372-376 1958;
    CrossrefPubMedGoogle Scholar
  • (19) Hougie C, Garrard M. E, Warren W. D, Dammann F, Muller W. H. Coagulation Problems Relating to the Use of the Extracorporeal Circulation in Man. Proceedings of the 7th Congress of the International Society of Blood Transfusion. Rome: 1958: 28 Edit. by Karger S. 1959.
    Google Scholar
  • (20) Spohn K, Kolb E, Heinzel J, Kratzert R, Wenz W, Woerner W, Lasch H. G, Sessner H. H, Raule W, Gottstein U, Kuhn E, Schreiner K. 30. Ergebnisse von Tierversuchen mit der Herz-Lungen-Maschine nach Crafoord-Senning. Langenbecks Archiv und Dtsch. Z. Chir. 289: 705-713 1958;
    PubMedGoogle Scholar
  • (21) Holemans R, Verstraete M, Joossens J. V. Clotting Deviations during complete cardiac Bypass. Is prepared.
    PubMedGoogle Scholar
  • (22) Verwilghen R. Verbruik van Prothrombine en Acceleratoren. Proefschrift Wedstrijd Reisbeurzen van de Belgische Staat; 1953
    Google Scholar